SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367601556> ?p ?o ?g. }

Showing items 1 to 100 of ±127 with 100 items per page.

W4367601556 endingPage "107237" @default.
W4367601556 startingPage "107237" @default.
W4367601556 abstract "A high relapse rate for patients with acute myeloid leukemia (AML) is still a major barrier to the long-term survival of these patients. Nevertheless, considerable progress has been made both in the biology and therapy of the disease. Specifically, progress has been made in the areas of integrated genomic analysis for prognosis, the widening application of minimal residual disease (MRD) monitoring in clinical practice, the development of new agents, and the increasing use of drugs, such as IDH and FLT3 inhibitors, as a bridge to transplant. Continued progress and inquiry into these and other areas are essential to improve the survival outcome for adult patients with AML." @default.
W4367601556 created "2023-05-02" @default.
W4367601556 creator A5000540634 @default.
W4367601556 creator A5009185638 @default.
W4367601556 creator A5016847474 @default.
W4367601556 creator A5021409687 @default.
W4367601556 creator A5024639718 @default.
W4367601556 creator A5030394477 @default.
W4367601556 creator A5032879380 @default.
W4367601556 creator A5033390935 @default.
W4367601556 creator A5033566401 @default.
W4367601556 creator A5037919647 @default.
W4367601556 creator A5040676059 @default.
W4367601556 creator A5042104274 @default.
W4367601556 creator A5042270042 @default.
W4367601556 creator A5048011835 @default.
W4367601556 creator A5048941818 @default.
W4367601556 creator A5049315625 @default.
W4367601556 creator A5052626249 @default.
W4367601556 creator A5053383868 @default.
W4367601556 creator A5055043268 @default.
W4367601556 creator A5056560175 @default.
W4367601556 creator A5056690267 @default.
W4367601556 creator A5058229630 @default.
W4367601556 creator A5065675161 @default.
W4367601556 creator A5066885861 @default.
W4367601556 creator A5067168605 @default.
W4367601556 creator A5067326780 @default.
W4367601556 creator A5069439760 @default.
W4367601556 creator A5069666873 @default.
W4367601556 creator A5072339482 @default.
W4367601556 creator A5076321659 @default.
W4367601556 creator A5076460585 @default.
W4367601556 creator A5079036666 @default.
W4367601556 creator A5080898639 @default.
W4367601556 creator A5081407092 @default.
W4367601556 creator A5084418142 @default.
W4367601556 creator A5087107827 @default.
W4367601556 creator A5087116680 @default.
W4367601556 creator A5088290764 @default.
W4367601556 creator A5090485086 @default.
W4367601556 date "2023-05-01" @default.
W4367601556 modified "2023-10-18" @default.
W4367601556 title "Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP" @default.
W4367601556 doi "https://doi.org/10.1016/j.leukres.2023.107237" @default.
W4367601556 hasPublicationYear "2023" @default.
W4367601556 type Work @default.
W4367601556 citedByCount "0" @default.
W4367601556 crossrefType "journal-article" @default.
W4367601556 hasAuthorship W4367601556A5000540634 @default.
W4367601556 hasAuthorship W4367601556A5009185638 @default.
W4367601556 hasAuthorship W4367601556A5016847474 @default.
W4367601556 hasAuthorship W4367601556A5021409687 @default.
W4367601556 hasAuthorship W4367601556A5024639718 @default.
W4367601556 hasAuthorship W4367601556A5030394477 @default.
W4367601556 hasAuthorship W4367601556A5032879380 @default.
W4367601556 hasAuthorship W4367601556A5033390935 @default.
W4367601556 hasAuthorship W4367601556A5033566401 @default.
W4367601556 hasAuthorship W4367601556A5037919647 @default.
W4367601556 hasAuthorship W4367601556A5040676059 @default.
W4367601556 hasAuthorship W4367601556A5042104274 @default.
W4367601556 hasAuthorship W4367601556A5042270042 @default.
W4367601556 hasAuthorship W4367601556A5048011835 @default.
W4367601556 hasAuthorship W4367601556A5048941818 @default.
W4367601556 hasAuthorship W4367601556A5049315625 @default.
W4367601556 hasAuthorship W4367601556A5052626249 @default.
W4367601556 hasAuthorship W4367601556A5053383868 @default.
W4367601556 hasAuthorship W4367601556A5055043268 @default.
W4367601556 hasAuthorship W4367601556A5056560175 @default.
W4367601556 hasAuthorship W4367601556A5056690267 @default.
W4367601556 hasAuthorship W4367601556A5058229630 @default.
W4367601556 hasAuthorship W4367601556A5065675161 @default.
W4367601556 hasAuthorship W4367601556A5066885861 @default.
W4367601556 hasAuthorship W4367601556A5067168605 @default.
W4367601556 hasAuthorship W4367601556A5067326780 @default.
W4367601556 hasAuthorship W4367601556A5069439760 @default.
W4367601556 hasAuthorship W4367601556A5069666873 @default.
W4367601556 hasAuthorship W4367601556A5072339482 @default.
W4367601556 hasAuthorship W4367601556A5076321659 @default.
W4367601556 hasAuthorship W4367601556A5076460585 @default.
W4367601556 hasAuthorship W4367601556A5079036666 @default.
W4367601556 hasAuthorship W4367601556A5080898639 @default.
W4367601556 hasAuthorship W4367601556A5081407092 @default.
W4367601556 hasAuthorship W4367601556A5084418142 @default.
W4367601556 hasAuthorship W4367601556A5087107827 @default.
W4367601556 hasAuthorship W4367601556A5087116680 @default.
W4367601556 hasAuthorship W4367601556A5088290764 @default.
W4367601556 hasAuthorship W4367601556A5090485086 @default.
W4367601556 hasConcept C126322002 @default.
W4367601556 hasConcept C143998085 @default.
W4367601556 hasConcept C2778461978 @default.
W4367601556 hasConcept C2778729363 @default.
W4367601556 hasConcept C2779134260 @default.
W4367601556 hasConcept C2779823535 @default.
W4367601556 hasConcept C2780007613 @default.
W4367601556 hasConcept C2780817109 @default.
W4367601556 hasConcept C3019894029 @default.
W4367601556 hasConcept C71924100 @default.